Epizyme files for a $69 million IPO

By
A A A

Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company recently entered into a collaboration agreement with Abbott Laboratories to develop a diagnostic to detect which patients would qualify for Epizyme's product candidates.

The Cambridge, MA-based company, which was founded in 2007 and booked $45 million in collaboration revenue for the 2012 fiscal year, plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on 3/22/2013. Primary backers include New Enterprise Associates (25.1% pre-IPO stake), Kleiner, Perkins, Caufield & Byers (20.1%), Bay City Capital (15.5%), Celgene European Investment Company (14.5%) and MPM Capital (12.8%). Citi, Cowen & Company, and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: EPZM

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

How to Save Money at Bars
How to Save Money at Bars           

Stocks

Referenced

Most Active by Volume

44,823,339
  • $75.19 ▲ 0.28%
43,744,171
  • $3.44 ▼ 0.29%
42,340,022
  • $97.671 ▲ 0.66%
34,178,145
  • $17.62 ▼ 1.23%
34,028,998
  • $15.59 ▼ 0.19%
32,055,708
  • $21.23 ▼ 2.41%
31,539,235
  • $3.76 ▲ 0.80%
30,434,619
    $34.25 unch
As of 7/25/2014, 04:03 PM